1-Uzunismail H, Bakan E, Yılmaz A, Akdemir D, Keleş M. Hyperamylasemia of uncommon origin: a case report. Biochimica Clinica 1990; 14:365-7.

2-Dobrucalı A, Canbakan B, Canbakan M, Bagatur N, Uzunismail H, Eralp Y, Akun E, Yurdakul I, Oktay E. Meta-anaysis of determining the pathogen eradicating efficacy of various therapeutic regimens in Helicobacter pylori infection. Wien Med Wochenschr 1998; 148 (20) :464-8.

3-Çelik AF, Pamuk GE, Pamuk ON, Doğusoy G, Uzunismail H . Should we suppress the antigenic stimulus in IPSID for life long?. Am J Gastroenterol 2000; 95 (11):3318-20.

4-Pamuk ON, Pamuk GE, Çelik A, Uzunismail H. Are Turkish  Helicobacter pylori strains gaining resistance against clarithromycin? Am J Gastroenterol 2000; 95 (7):1839-40.

5-Canbakan B, Dobrucalı A, Celik A, Canbakan M, Bal K, Erzin Y, Göksel S, Uzunismail H, Yurdakul I, Oktay E, Hekim N, Dündar G. Gastritis localization and GERD incidence in patients with Cag A(+) and Cag A(-) Helicobacter pylori infection. Wien Med Wochenschr 2000; 150 (5):91-3.

6-Özçelik D, Eralp Y, Öztekin G, Dursun S, Uzunismail H. The impact of penicillamine and zinc in hepatic and brain tissues of copper-overloaded. Trace Elem Electrolytes 2001; 18:34-8.

7-Çelik AF, Demirkesen C, Pamuk ON, Pamuk GE, Uzunismail H. How prevalent are alterations in bowel habits during menses? Dis colon Rectum 2001; 44(2):300-1.

8-Tahan V, Özaras R, Uzunismail H, Mert A, Tabak F, Aktuğlu Y, Özbay G. Infectious mononucleosis presenting with severe cholestatic liver disease in the elderly. J Clin Gastroenterol 2001; 33: 88-9.

9-S. Telaku, İ. Hatemi, S. Erdamar, K.Bal. H. Uzunismail. Krahassimi protokolleve 1 dhe 2 javore me lansaprazole-amoxicllin-clarithromycin ne eredikimin e Helicobacter pylori. Praxis Medica 2005; 46:23-27.

10- Uzunismail H, Hatemi I, Doğusaoy G, Akın O. Dense eosinophilic infiltration of mucosa preceding ulcerative colitis and mimicking eosinophilic colitis: report of two cases. Turk J Gastroenterol 2006; 17(1) 53-7.

11-Erzin Y, Uzun H, Celik AF, Aydin S, Dirican A, Uzunismail H. Hyperhomo-cysteinemia in inflammatory bowel disease patients without past intestinal resections: Correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity and prior thromboembolic complications. J Clin Gastroenterol 2008; 42: 481-6 [ Research article ].

12-Erzin Y, Telaku S, Yirmibeşcik S, Celik AF, Dirican A, Uzunismail H. Prevalence of appendectomy and tonsillectomy in patients with inflammatory bowel disease: a case-control study. Turk J Gastroenterol 2008; 19: 199-200 [ Letter to the editor].

13-Uzunismail H, Goksel S, Cagatay P, Cengiz M. PPIs and food allergy. Am J Gastroenterol 2010; 105(4):963-4.

14-Uzunismail H, Cengiz M, Uzun H, Özbakır F, Göksel S, Demirdağ F, Can G, Balcı H. The effects of provocation by foods with raised  IgG antibodies and additives on the caurse of Crohn’s disease: A pilot study. Turk J Gastroenterol 2012; 23:19-27.

15. Uzunismail H.Possible Mechanism of Symptomatic Improvement with IgG Antibody- guided Exclusion Diet in Inflammatory Bowel Disease and Irritable Bowel Syndrome.  J Inflam Bowel Dis Disor 2018, 3:2. DOI: 10.4172/2746-1958.1000128

16.Uzunismail H. May the Activation of Mast Cells by IgG- Food Antigen Complexes be the Missing Piece of Irritable Bowel Syndrome Puzzle? Gastroenterol Hepatol Open Access. 2020;11(1):47‒50

17. Uzunismail H. Increased Mast Cell Activation may be Responsible for the Critical Conditions in COVID-19 and Targeting Mast Cells and Their Mediators can Bring New Treatment Prospects. Microbiol Infect Dis. 2020; 4(3): 1-6.

18. Uzunismail H. Evaluation of Food Specific Immunoglobulin G (IgG)-Guided Exclusion Diet in the Treatment of Irritable Bowel Syndrome and Inflammatory Bowel disease. Edel J Biomed Edel J Biomed. 2020;2:14-19